Australian biotechnology company Prima BioMed Ltd is one of the world's leaders when it comes to cancer treatment. We focus on developing anti-cancer therapeutics based on the emerging technology of immunotherapy. Scientific research, product development and clinical trials are the essentials of what we call the cutting edge of the fight against cancer.

Product Development

The company has 3 programs in place. The lead program, CVac™ has completed Phase IIa clinical trials and focuses on the development of an ex vivo immunotherapy for ovarian cancer. >>

Scientific Research

Prima BioMed's technologies all result from research on the human immune system. In summary, the technology platforms behind the Product Pipeline are: Dendritic cell therapy, Monoclonal Antibodies, DCtagTM adjuvant. >>

Clinical Trial

CVac™ cell therapy is a new and groundbreaking technology for the treatment of cancer. It stimulates the production of immune cells, produced naturally in the body, that attack cancer cells. >>

Latest News

02 February 2010
A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy with a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission >>

27 January 2010
Quarterly Activity Report 31 Dec 2009 >>

22 January 2010
Matthew Lehman Appointed New Chief Operating Officer >>

Read more news >>

Press and Video

Movie about Cancer Vac >>
Channel 7 News >>
Channel 10 News >>